8-Desacetyl-8-carboxy daunorubicin

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H27NO11
Molecular Weight	529.4927
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of 8-Desacetyl-8-carboxy daunorubicin

Structure Search

SMILES

[H][C@@]1(C[C@H](N)[C@H](O)[C@H](C)O1)O[C@H]2C[C@@](O)(CC3=C2C(O)=C4C(=O)C5=C(OC)C=CC=C5C(=O)C4=C3O)C(O)=O

InChI

InChIKey=UOZJSBYGENSCDJ-FHRHSTJFSA-N

InChI=1S/C26H27NO11/c1-9-20(28)12(27)6-15(37-9)38-14-8-26(35,25(33)34)7-11-17(14)24(32)19-18(22(11)30)21(29)10-4-3-5-13(36-2)16(10)23(19)31/h3-5,9,12,14-15,20,28,30,32,35H,6-8,27H2,1-2H3,(H,33,34)/t9-,12-,14-,15-,20+,26-/m0/s1

HIDE SMILES / InChI

Approval Year

Name

Type

Language

8-Desacetyl-8-carboxy daunorubicin

Common Name

English

Doxorubicin Impurity 6

Common Name

English

2-Naphthacenecarboxylic acid, 4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-, (2S,4S)-

Systematic Name

English

(2S,4S)-4-(((2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-carboxylic acid

Systematic Name

English

2-Naphthacenecarboxylic acid, 4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-, (2S-cis)-

Systematic Name

English

(2S,4S)-4-[(3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenecarboxylic acid

Systematic Name

English

4-[(3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenecarboxylic acid, (2S,4S)-

Systematic Name

English

Code System Code Type Description

CAS

69429-21-6

Created by admin on Sat Dec 16 19:53:40 GMT 2023 , Edited by admin on Sat Dec 16 19:53:40 GMT 2023

PRIMARY

PUBCHEM

52947885

Created by admin on Sat Dec 16 19:53:40 GMT 2023 , Edited by admin on Sat Dec 16 19:53:40 GMT 2023

PRIMARY

FDA UNII